Clinical stage immuno-oncology company Trillium Therapeutics has begun dosing in its second Phase I clinical trial of TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously accessible solid tumours and mycosis fungoides.

TTI-621 is a fusion protein designed as a checkpoint inhibitor of the innate immune system and consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

The drug prevents CD47 from generating the inhibitory signal by acting as a soluble decoy receptor.

The two-part, multi-centre, open-label Phase Ia/Ib trial will evaluate TTI-621 as a single-agent in these patients.

"To our knowledge, this is the first patient to ever receive an intratumoral injection of a CD47 blocking agent."

Trillium chief scientific officer Bob Uger said: "To our knowledge, this is the first patient to ever receive an intratumoral injection of a CD47 blocking agent.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We believe this approach, which aims to achieve a high local concentration of TTI-621 and employs frequent biopsy analysis, will help us better understand the effects of TTI-621 on the tumour microenvironment and provide critical information for the development of rational combination therapies."

The study will also include an escalation phase with single or multiple doses of TTI-621 administered by intratumoral injections, as well as an expansion phase, which will test one or more selected dose levels of TTI-621.

The drug is currently undergoing a 10-cohort Phase Ib study in patients with relapsed or refractory hematologic malignancies.

Image: Skin lesions on the knee of a 52 year old male patient with Mycosis fungoides. Photo: courtesy of Bobjgalindo/Wikipedia.